Compare DCM Shriram Fine with Similar Stocks
Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- The company has reported losses. Due to this company has reported negative ROE
- PAT(Q) At Rs -4.08 cr has Fallen at -866.2% (vs previous 4Q average)
- NET SALES(Q) Lowest at Rs 93.08 cr
- PBDIT(Q) Lowest at Rs -2.50 cr.
Risky - Negative Operating Profits
Falling Participation by Institutional Investors
Stock DNA
Commodity Chemicals
INR 234 Cr (Micro Cap)
NA (Loss Making)
42
0.00%
0.00
0.00%
0.00
Total Returns (Price + Dividend) 
DCM Shriram Fine for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Are DCM Shriram Fine Chemicals Ltd latest results good or bad?
DCM Shriram Fine Chemicals Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported a net loss of ₹3.83 crores, marking a substantial decline compared to the previous year, and this is the third consecutive quarter of losses. The operating margin turned negative at -2.71%, a stark contrast to the positive margin of 6.78% in Q4 FY25, indicating a complete erosion of profitability. Net sales for the quarter were ₹93.08 crores, reflecting a slight year-on-year decline of 0.29% and a more pronounced quarter-on-quarter decrease of 3.99%. This drop in sales represents the lowest quarterly figure in the company’s recent history, highlighting ongoing operational distress. The operating profit (PBDIT excluding other income) fell to ₹-2.51 crores, a dramatic shift from the ₹7.63 crores reported in the same quarter last year. The financial metrics illustrate a concer...
Read full news article
DCM Shriram Fine Chemicals Q4 FY26: Steep Losses Mount as Operational Crisis Deepens
DCM Shriram Fine Chemicals Ltd., a micro-cap commodity chemicals manufacturer with a market capitalisation of ₹234.00 crores, reported a devastating quarterly loss in Q4 FY26, marking a dramatic reversal from profitability just a year ago. The company posted a consolidated net loss of ₹3.83 crores for the March 2026 quarter, a stark contrast to the ₹4.42 crores profit recorded in Q4 FY25, representing a year-on-year decline of 260.25%. The stock reacted sharply to the results, declining 4.97% to ₹26.94 in Tuesday's trading session, reflecting investor concerns about the company's deteriorating operational performance.
Read full news article Announcements 
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 2 Schemes (0.0%)
Held by 36 FIIs (1.48%)
Lala Bansi Dhar & Sons (13.83%)
Life Insurance Corporation Of India (4.64%)
25.61%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is -3.68% vs -0.22% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is -151.85% vs 40.44% in Dec 2025
Annual Results Snapshot (Standalone) - Mar'26
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period






